Clinical trials: Cancer Patient
Advanced Non-small Cell Lung Cancer (NSCLC)
AMT-116 in Combination With AK112 in Patients With Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT07590531
- Testing
- AMT-116, AK112
- Where
- 2 sites in China
- Volunteers
- 118 people
- Sponsor
- Multitude Therapeutics Inc.
Solid Tumors
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer…
- Trial name
- NCT07415031
- Testing
- Adagrasib, Pembrolizumab, Cetuximab
- Where
- 101 sites in United States, Australia and 19 more
- Volunteers
- 170 people
- Sponsor
- Mirati Therapeutics Inc.
Malignant Solid Tumors
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.
- Trial name
- NCT06737731
- Testing
- SHR-1681
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
A Study YL201 in Patients With Selected Advanced Solid Tumors
This is A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors.
- Trial name
- NCT06057922
- Testing
- YL201 for Injection
- Where
- 52 sites in China
- Volunteers
- 990 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Gastrointestinal Neoplasm
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies…
- Trial name
- NCT00094029
- Testing
- Sutent
- Where
- 118 sites in United States, Argentina and 32 more
- Sponsor
- Pfizer
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses.
- Conditions
- HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
- Trial name
- HER2 (NCT05650879)
- Testing
- ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 198 people
- Sponsor
- Enliven Therapeutics
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer
This is a phase-3, open-label, multicenter, two-arm treatment study to evaluate the efficacy and safety of weekly Paclitaxel Lipid Suspension compared with weekly conventional paclitaxel in participants with…
- Conditions
- Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer, Platinum Resistant High Grade Serous Ovarian Cancer
- Trial name
- NCT06867562
- Testing
- Paclitaxel Lipid Suspension, Conventional paclitaxel or Taxol
- Volunteers
- 166 people
- Sponsor
- Jina Pharmaceuticals Inc.
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
This Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
- Trial name
- Catalyst (NCT05383170)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 6 people
- Sponsor
- Cytovation AS
Advanced or Metastatic Solid Tumors
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors.
- Trial name
- NCT05785754
- Testing
- DCSZ11, Pembrolizumab, Doxorubicin
- Where
- 35 sites in United States, Australia and 2 more
- Volunteers
- 320 people
- Sponsor
- DynamiCure Biotechnology
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Non-Hodgkin's Lymphoma
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL)…
- Trial name
- NCT00312845
- Testing
- Bortezomib + Rituximab, Rituximab
- Where
- 206 sites in United States, Argentina and 30 more
- Volunteers
- 676 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer Metastatic Castration-Resistant
A Study of KMV002 in Patients With mAPMR Prostate Cancer
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients.
- Trial name
- NCT07866300
- Testing
- KMV002
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Chimivac INC
Cancer of Endometrium, Cancer of Cervix
Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients
Pain relief following laparotomy surgery requires a variety of techniques including invasive ones like epidural or nerve blocks along with different classes of drugs, out of which opioids are most predominant.
- Trial name
- NCT05742711
- Testing
- Primary Relief
- Where
- India
- Volunteers
- 48 people
- Sponsor
- DyAnsys, Inc.
Tumors, Hypoxia
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors.
- Trial name
- NCT00495144
- Testing
- TH-302
- Where
- 7 sites in United States
- Volunteers
- 129 people
- Sponsor
- Threshold Pharmaceuticals
Glioblastoma Multiforme
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
This is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor…
- Trial name
- TEM-GBM (NCT03866109)
- Testing
- Temferon
- Where
- 3 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Genenta Science
Melanoma
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
The purpose of this study is to evaluate whether vaccination with a Melan-A VLP vaccine leads to a specific cellular immune response in patients with malignant melanoma at advanced stage of the disease.
- Trial name
- NCT00306514
- Testing
- CYT004-MelQbG10
- Where
- Germany
- Sponsor
- Cytos Biotechnology AG
Prostate Cancer
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
The purpose of this trial is to compare the severity of ISRs (Injection Site Reactions) following degarelix subcutaneous (s.c.) administrations with two different injection techniques and intramuscular (i.m.) administration in…
- Trial name
- NCT02526784
- Testing
- degarelix
- Where
- 3 sites in Finland, France and 1 more
- Volunteers
- 120 people
- Sponsor
- Ferring Pharmaceuticals
Colorectal Cancer Stage II, Colorectal Cancer Stage III
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer…
- Trial name
- NCT04486378
- Testing
- RO7198457 intravenous (IV), Observational group (no intervention)
- Where
- 85 sites in United States, Belgium and 5 more
- Volunteers
- 327 people
- Sponsor
- BioNTech SE
Advanced Non-Hematologic Malignancies
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive…
- Trial name
- NCT00915278
- Testing
- PF-04605412
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.